Across all genders and ethnic groups, cardiovascular disease is the leading cause of death in the United States. It is estimated that 8.8 million adults above age 20 have had a heart attack, and 7.6 million have had a stroke. These events can occur for many reasons, but a lesser-known risk factor is elevated lipoprotein(a) (Lp(a)).
Because of the prevalence of cardiovascular disease and how little is known about Lp(a)’s impact on it, our client designed a large study to evaluate how the reduction of Lp(a) affected the risk for major cardiac events. The client also needed this trial to launch in 6 weeks instead of the usual 12, but Antidote was ready to tackle the challenge.
We quickly began planning our outreach strategy, leveraging our third-party partnerships and digital ad expertise to find potentially eligible participants. Through population research, data-driven patient models, and a hands-on outreach optimization strategy, we were able to deliver 80 randomizations at a 96% randomization rate.
For more details, download the case study.
